Drug Profile

Eptotermin alfa - Olympus Biotech

Alternative Names: Opgenra; Osigraft

Latest Information Update: 24 Jan 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Olympus Biotech Europe SAS
Class Bone morphogenetic proteins; Calcium regulators; Osteoporosis therapies; Recombinant proteins
Mechanism of Action Apoptosis inhibitors; Collagen stimulants; Matrix metalloproteinase 13 modulators; Proteoglycan stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Non-union fracture; Spondylolisthesis

Most Recent Events

24 Jan 2019 Eptotermin alfa is not yet available for Spondylisthesis (In adults) in Iceland, Norway and Liechtenstein (Implant)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com